Marvell Technology Group Ltd. (NASDAQ:MRVL) has earned a price target raise to $90 from $80 from Bank of America analysts, who repeated their ‘Buy’ rating following the company’s recent AI event.
“We continue to like Marvell as the rising tide of AI capex can help drive potential upside for one of the few franchises with a singular data-center focus, and with breadth of leading IP across compute, XPU, networking, electro-optics, security, and memory/storage,” the analysts wrote.
The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shift in attitude towards psychedelic therapies under the Trump administration.
Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, unlike full FDA approval, they require a lower standard of evidence, a report from health-oriented news website Stat published on Wednesday highlighted.
Tiger Royalties and Investments (AIM: TIR) jumped 55% on Wednesday after revealing that its newly acquired Tiger Alpha Bittensor Subnet is generating nearly $70,000 in monthly revenue, just a month after going live.
The subnet, a revenue-generating node on the decentralised Bittensor blockchain, is producing over six TAO per day, worth more than $2,300 at current prices.